首页MVIR • STO
add
Medivir AB
昨日收盘价
kr 2.70
当日价格范围
kr 2.66 - kr 2.74
年度波幅
kr 2.33 - kr 4.71
市值
3.04亿 SEK
平均交易量
8.97万
市盈率
-
股息率
-
主要交易所
STO
市场资讯
财务信息
损益表
收入
净收入
| (SEK) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 90.00万 | 12.50% |
经营支出 | 730.00万 | 5.80% |
净收入 | -3460.00万 | -46.61% |
净利润率 | -3844.44 | -30.32% |
每股收益 | -0.30 | 28.57% |
息税折旧摊销前利润 | -3530.00万 | -50.21% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (SEK) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 9250.00万 | 51.39% |
总资产 | 2.04亿 | 15.96% |
负债总额 | 6240.00万 | 20.93% |
权益总额 | 1.42亿 | — |
发行在外的股份 | 1.12亿 | — |
市净率 | 2.14 | — |
资产回报率 | -40.60% | — |
资本回报率 | -53.35% | — |
现金流
现金净变动
| (SEK) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -3460.00万 | -46.61% |
来自运营的现金 | -3340.00万 | -59.05% |
投资现金 | — | — |
融资现金 | -60.00万 | 0.00% |
现金净变动 | -3410.00万 | -57.14% |
自由现金流 | -2180.00万 | -71.32% |
简介
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
CEO
成立时间
1988
员工数量
10
